AR073622A1 - Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos - Google Patents
Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticosInfo
- Publication number
- AR073622A1 AR073622A1 ARP090103611A ARP090103611A AR073622A1 AR 073622 A1 AR073622 A1 AR 073622A1 AR P090103611 A ARP090103611 A AR P090103611A AR P090103611 A ARP090103611 A AR P090103611A AR 073622 A1 AR073622 A1 AR 073622A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- psychotic disorders
- dopamine
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 3
- 101150104779 HTR2A gene Proteins 0.000 title abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012239 Delusion Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- 206010033864 Paranoia Diseases 0.000 abstract 1
- 208000027099 Paranoid disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 231100000868 delusion Toxicity 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Los compuestos activos de la presente invencion son moduladores duales de los receptores de la serotonina 5-HT2a y de la dopamina D3, utiles para el tratamiento y/o la prevencion de trastornos cognitivos, adiccion a las drogas, depresion, ansiedad, dependencia de las drogas, demencias, desequilibrio de la memoria, trastornos psicoticos incluida la esquizofrenia, trastornos esquizoafectivos, trastorno bipolar, trastornos psicoticos maníaco-depresivos y psicosis, incluida la paranoia y los delirios. Reivindicacion 1: Un compuesto de la formula (1) en la que: X se elige con independencia de su aparicion entre halogeno y alquilo C1-6; n es el numero 0, 1 o 2; R1 es -CO-R2 o -SO2-alquilo C1-6; R2 es alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, cicloalquilo de 3 a 10 eslabones, heterocicloalquilo de 4 a 10 eslabones o heteroarilo de 5 a 10 eslabones, que están opcionalmente sustituidos por uno o más sustituyentes elegidos entre el grupo formado por: halogeno, hidroxi, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, alcoxi C1-6 opcionalmente sustituido por uno o más Ra, -S-alquilo C1-6, -SO2-alquilo C1-6, -CONH2, -CHO, cicloalquilo de 3 a 10 eslabones opcionalmente sustituido por uno o más Ra, heterocicloalquilo de 4 a 10 eslabones opcionalmente sustituido por uno o más Ra y heteroarilo de 5 a 10 eslabones opcionalmente sustituido por uno o más Ra; en los que Ra se elige entre el grupo formado por: halogeno, hidroxi, alquilo C1-6, hidroxialquilo C1-6, haloalquilo C1-6 y alcoxi C1-6; así como las sales y ésteres farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164802 | 2008-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073622A1 true AR073622A1 (es) | 2010-11-17 |
Family
ID=41226238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103611A AR073622A1 (es) | 2008-09-22 | 2009-09-21 | Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7858630B2 (es) |
| EP (1) | EP2334657B1 (es) |
| JP (1) | JP5367824B2 (es) |
| KR (1) | KR101329548B1 (es) |
| CN (1) | CN102159557A (es) |
| AR (1) | AR073622A1 (es) |
| AU (1) | AU2009294695B2 (es) |
| BR (1) | BRPI0918949A2 (es) |
| CA (1) | CA2735400A1 (es) |
| ES (1) | ES2402875T3 (es) |
| IL (1) | IL210769A0 (es) |
| MX (1) | MX2011002628A (es) |
| TW (1) | TW201016687A (es) |
| WO (1) | WO2010031735A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000032987A (ja) * | 1998-07-16 | 2000-02-02 | Dai Ichi Seiyaku Co Ltd | Ｄｎａ |
| AU2008280187B2 (en) * | 2007-07-26 | 2013-05-16 | F. Hoffmann-La Roche Ag | Dual modulators of 5-HT2A and D3 receptors |
| KR20110076944A (ko) * | 2008-09-23 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | 도파민 ｄ3 수용체의 조절제로서 유용한 이속사졸로〔4,5〕피리딘-3-일-피페라진 유도체 |
| US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8722683B2 (en) | 2011-02-17 | 2014-05-13 | Hoffmann La-Roche Inc. | Benzodioxole piperazine compounds |
| US8598357B2 (en) | 2011-03-03 | 2013-12-03 | Hoffmann-La Roche Inc. | Benzodioxole piperidine compounds |
| JP5964615B2 (ja) * | 2011-03-28 | 2016-08-03 | 住友化学株式会社 | ポジ型レジスト組成物 |
| US8921397B2 (en) * | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| JP6061934B2 (ja) | 2011-08-25 | 2017-01-18 | シンジェンタ パーティシペーションズ アーゲー | 殺虫化合物としてのイソオキサゾリン誘導体 |
| WO2013026929A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Dihydropyrrole derivatives as insecticidal compounds |
| BR112014004275A2 (pt) | 2011-08-25 | 2017-03-21 | Syngenta Participations Ag | derivados de isoxazolina como compostos inseticidas |
| US9204648B2 (en) | 2011-08-25 | 2015-12-08 | Syngenta Participations Ag | Process for the preparation of thietane derivatives |
| WO2013026695A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
| UY35420A (es) * | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| CN104140421B (zh) | 2013-05-08 | 2017-04-05 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 |
| CN106518841B (zh) * | 2015-09-15 | 2019-03-05 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
| WO2017045599A1 (zh) * | 2015-09-15 | 2017-03-23 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
| US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
| CN107793408B (zh) * | 2016-09-05 | 2020-12-08 | 上海医药工业研究院 | 哌啶氨基衍生物及其治疗精神分裂症的应用 |
| CN107793350B (zh) * | 2016-09-05 | 2021-06-04 | 上海医药工业研究院 | 芳乙基哌啶基衍生物及其治疗精神分裂症的应用 |
| CN106543017B (zh) * | 2016-11-10 | 2018-04-06 | 中国科学院青岛生物能源与过程研究所 | 一种4‑氨基‑环己乙酸的制备方法 |
| WO2019146740A1 (ja) * | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| EP3744721A4 (en) | 2018-01-26 | 2021-11-10 | Shionogi & Co., Ltd | CONDENSED CYCLIC COMPOUND WITH ANTAGONISM TO DOPAMINE D3 RECEPTOR |
| CN110872272A (zh) * | 2018-08-30 | 2020-03-10 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的盐 |
| CN113056454A (zh) | 2019-10-29 | 2021-06-29 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
| JP2023501306A (ja) * | 2019-11-05 | 2023-01-18 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ベンゾチオフェン誘導体レギュレーター、その調製法及び使用 |
| AU2022266937A1 (en) | 2021-04-28 | 2023-10-19 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| EP1362039B1 (en) | 2001-02-16 | 2005-12-21 | Aventis Pharmaceuticals Inc. | Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| CN1701072A (zh) * | 2002-09-17 | 2005-11-23 | 沃纳-兰伯特公司 | 用于治疗精神分裂症的杂环取代的哌嗪 |
| BR0314393A (pt) | 2002-09-17 | 2005-07-19 | Warner Lambert Co | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia |
| WO2004041793A1 (en) * | 2002-11-08 | 2004-05-21 | Warner-Lambert Company Llc | Phenylalkyl and pyridylalkyl piperazine derivatives |
| BRPI0410378A (pt) | 2003-05-16 | 2006-06-13 | Pfizer Prod Inc | tratamento de distúrbios psicóticos e depressivos |
| JP2007522095A (ja) | 2003-05-16 | 2007-08-09 | ファイザー・プロダクツ・インク | ジプラシドンを用いた不安の治療 |
| CN101384581B (zh) * | 2006-02-17 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物 |
| BRPI0707960A2 (pt) | 2006-02-17 | 2011-05-10 | Hoffmann La Roche | derivados de benzoil-piperidina como moduladores de 5ht2/d3, medicamento e uso dos mesmos |
| AU2008280187B2 (en) * | 2007-07-26 | 2013-05-16 | F. Hoffmann-La Roche Ag | Dual modulators of 5-HT2A and D3 receptors |
| FR2926979B1 (fr) | 2008-02-04 | 2010-12-17 | Oreal | Nouveaux composes cationiques, compositions les comprenant, utilisation comme conditionneur, et procede de traitement cosmetique. |
-
2009
- 2009-09-11 BR BRPI0918949A patent/BRPI0918949A2/pt not_active IP Right Cessation
- 2009-09-11 JP JP2011527297A patent/JP5367824B2/ja not_active Expired - Fee Related
- 2009-09-11 KR KR1020117006453A patent/KR101329548B1/ko not_active IP Right Cessation
- 2009-09-11 MX MX2011002628A patent/MX2011002628A/es active IP Right Grant
- 2009-09-11 ES ES09782901T patent/ES2402875T3/es active Active
- 2009-09-11 CN CN2009801369519A patent/CN102159557A/zh active Pending
- 2009-09-11 AU AU2009294695A patent/AU2009294695B2/en not_active Ceased
- 2009-09-11 EP EP09782901A patent/EP2334657B1/en not_active Not-in-force
- 2009-09-11 CA CA2735400A patent/CA2735400A1/en not_active Abandoned
- 2009-09-11 WO PCT/EP2009/061788 patent/WO2010031735A1/en active Application Filing
- 2009-09-16 US US12/560,459 patent/US7858630B2/en not_active Expired - Fee Related
- 2009-09-21 AR ARP090103611A patent/AR073622A1/es unknown
- 2009-09-21 TW TW098131802A patent/TW201016687A/zh unknown
-
2011
- 2011-01-20 IL IL210769A patent/IL210769A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110045071A (ko) | 2011-05-03 |
| US20100075983A1 (en) | 2010-03-25 |
| BRPI0918949A2 (pt) | 2019-09-24 |
| AU2009294695B2 (en) | 2012-09-13 |
| TW201016687A (en) | 2010-05-01 |
| WO2010031735A1 (en) | 2010-03-25 |
| IL210769A0 (en) | 2011-03-31 |
| KR101329548B1 (ko) | 2013-11-18 |
| ES2402875T3 (es) | 2013-05-10 |
| CA2735400A1 (en) | 2010-03-25 |
| AU2009294695A1 (en) | 2010-03-25 |
| EP2334657B1 (en) | 2013-03-06 |
| JP5367824B2 (ja) | 2013-12-11 |
| US7858630B2 (en) | 2010-12-28 |
| EP2334657A1 (en) | 2011-06-22 |
| MX2011002628A (es) | 2011-04-05 |
| CN102159557A (zh) | 2011-08-17 |
| JP2012502944A (ja) | 2012-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073622A1 (es) | Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos | |
| AR126406A2 (es) | Compuestos de tetrazolinona y su uso | |
| CU20180145A7 (es) | Compuestos derivados (piperidin-1-il)(piperidin-4-il) metanona, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| PE20181197A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| CU20150056A7 (es) | Derivados e 1h- bencimidazol como antagonistas de ep4 y medicamentos que los contienen | |
| NI201500106A (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno. | |
| AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
| PE20141556A1 (es) | Derivados de etinilo como moduladores alostericos de mglur5 | |
| GT200600166A (es) | Derivados de cromano y cromeno y usos de los mismos | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| CO6361937A2 (es) | Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| ECSP11011288A (es) | Derivados de indol como antagonistas del receptor crth2 | |
| PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| AR058151A1 (es) | Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion | |
| CU24038B1 (es) | Derivados de sulfonamidas útiles para el tratamiento de enfermedades que respondan a los mediadores del receptor cxcr2 | |
| PA8815001A1 (es) | Piridinil amidas para el tratamiento de trastornos del snc y metabolicos | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| AR090587A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| UY30938A1 (es) | Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones. | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| AR067648A1 (es) | Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |